Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Catheter Precision ( (VTAK) ) has shared an update.
On June 2, 2025, Catheter Precision, Inc. announced the discontinuation of employment for their Chief Commercial Officer, Marie-Claude Jacques. Executive Chairman and CEO David Jenkins will temporarily assume the role until a new replacement is found, which may impact the company’s commercial operations and leadership dynamics.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Underperform.
The overall stock score of 40 reflects significant challenges, primarily driven by poor financial performance with negative growth and cash flow issues. Technical analysis indicates bearish trends, and the valuation perspective is unattractive due to a negative P/E ratio. The recent stock offering further exacerbates the outlook with dilution concerns, overshadowing the modest balance sheet stability.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Average Trading Volume: 581,277
Technical Sentiment Signal: Sell
Current Market Cap: $2.22M
See more data about VTAK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue